HLA-A*02:01
|
Uveal Melanoma
|
HLA-A*02:01
|
Uveal Melanoma
|
tebentafusp Sensitive: A1 - Approval
|
tebentafusp Sensitive: A1 - Approval
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
TC Sensitive: A2 - Guideline
|
TC Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
ipilimumab Sensitive: A2 - Guideline
|
ipilimumab Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
dacarbazine Sensitive: A2 - Guideline
|
dacarbazine Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
temozolomide Sensitive: A2 - Guideline
|
temozolomide Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
trametinib Sensitive: A2 - Guideline
|
trametinib Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
CaT Sensitive: A2 - Guideline
|
CaT Sensitive: A2 - Guideline
|
HLA-A2 positive
|
Uveal Melanoma
|
HLA-A2 positive
|
Uveal Melanoma
|
tebentafusp Sensitive: B - Late Trials
|
tebentafusp Sensitive: B - Late Trials
|
BRAF V600
|
Ocular Melanoma
|
BRAF V600
|
Ocular Melanoma
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
BRAF V600
|
Ocular Melanoma
|
BRAF V600
|
Ocular Melanoma
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
Ocular Melanoma
|
BRAF V600E
|
Ocular Melanoma
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
GNA11 mutation
|
Uveal Melanoma
|
GNA11 mutation
|
Uveal Melanoma
|
selumetinib Sensitive: C2 – Inclusion Criteria
|
selumetinib Sensitive: C2 – Inclusion Criteria
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
trametinib Sensitive: C2 – Inclusion Criteria
|
trametinib Sensitive: C2 – Inclusion Criteria
|
MBD4 mutation
|
Uveal Melanoma
|
MBD4 mutation
|
Uveal Melanoma
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
CXCL10 elevation
|
Uveal Melanoma
|
CXCL10 elevation
|
Uveal Melanoma
|
tebentafusp Sensitive: C3 – Early Trials
|
tebentafusp Sensitive: C3 – Early Trials
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
GNA11 mutation
|
Uveal Melanoma
|
GNA11 mutation
|
Uveal Melanoma
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
GNA11 Q209L
|
Uveal Melanoma
|
GNA11 Q209L
|
Uveal Melanoma
|
IDE196 Sensitive: C3 – Early Trials
|
IDE196 Sensitive: C3 – Early Trials
|
LDH-H
|
Uveal Melanoma
|
LDH-H
|
Uveal Melanoma
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
LDH-H
|
Uveal Melanoma
|
LDH-H
|
Uveal Melanoma
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
cabozantinib capsule Sensitive: C3 – Early Trials
|
cabozantinib capsule Sensitive: C3 – Early Trials
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
AEB071 Sensitive: C3 – Early Trials
|
AEB071 Sensitive: C3 – Early Trials
|
GNA11 mutation
|
Uveal Melanoma
|
GNA11 mutation
|
Uveal Melanoma
|
AEB071 Sensitive: C3 – Early Trials
|
AEB071 Sensitive: C3 – Early Trials
|
LDH-H
|
Uveal Melanoma
|
LDH-H
|
Uveal Melanoma
|
ipilimumab Sensitive: C3 – Early Trials
|
ipilimumab Sensitive: C3 – Early Trials
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
selumetinib Sensitive: C3 – Early Trials
|
selumetinib Sensitive: C3 – Early Trials
|
GNA11 Q209L
|
Uveal Melanoma
|
GNA11 Q209L
|
Uveal Melanoma
|
selumetinib Sensitive: C3 – Early Trials
|
selumetinib Sensitive: C3 – Early Trials
|
GNA11 mutation
|
Uveal Melanoma
|
GNA11 mutation
|
Uveal Melanoma
|
cabozantinib capsule Sensitive: C3 – Early Trials
|
cabozantinib capsule Sensitive: C3 – Early Trials
|
DDX43 overexpression
|
Uveal Melanoma
|
DDX43 overexpression
|
Uveal Melanoma
|
selumetinib Resistant: C3 – Early Trials
|
selumetinib Resistant: C3 – Early Trials
|
KRAS overexpression
|
Uveal Melanoma
|
KRAS overexpression
|
Uveal Melanoma
|
selumetinib Resistant: C3 – Early Trials
|
selumetinib Resistant: C3 – Early Trials
|
NRAS overexpression
|
Uveal Melanoma
|
NRAS overexpression
|
Uveal Melanoma
|
selumetinib Resistant: C3 – Early Trials
|
selumetinib Resistant: C3 – Early Trials
|
PCSK9 underexpression
|
Uveal Melanoma
|
PCSK9 underexpression
|
Uveal Melanoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
IL6 elevation
|
Uveal Melanoma
|
IL6 elevation
|
Uveal Melanoma
|
tebentafusp Sensitive: C3 – Early Trials
|
tebentafusp Sensitive: C3 – Early Trials
|
LDH-L
|
Uveal Melanoma
|
LDH-L
|
Uveal Melanoma
|
pembrolizumab + SNDX-275 Sensitive: C3 – Early Trials
|
pembrolizumab + SNDX-275 Sensitive: C3 – Early Trials
|
GNAQ G48L + FGFR4 C172G
|
Uveal Melanoma
|
GNAQ G48L + FGFR4 C172G
|
Uveal Melanoma
|
trametinib Sensitive: C4 – Case Studies
|
trametinib Sensitive: C4 – Case Studies
|
MBD4 mutation
|
Uveal Melanoma
|
MBD4 mutation
|
Uveal Melanoma
|
pembrolizumab Sensitive: C4 – Case Studies
|
pembrolizumab Sensitive: C4 – Case Studies
|
MBD4 L563T
|
Uveal Melanoma
|
MBD4 L563T
|
Uveal Melanoma
|
pembrolizumab + ipilimumab Sensitive: C4 – Case Studies
|
pembrolizumab + ipilimumab Sensitive: C4 – Case Studies
|
BRAF V600E
|
Uveal Melanoma
|
BRAF V600E
|
Uveal Melanoma
|
pembrolizumab + encorafenib + binimetinib Sensitive: C4 – Case Studies
|
pembrolizumab + encorafenib + binimetinib Sensitive: C4 – Case Studies
|
MLANA expression + SOX10 expression
|
Ocular Melanoma
|
MLANA expression + SOX10 expression
|
Ocular Melanoma
|
mitomycin Sensitive: C4 – Case Studies
|
mitomycin Sensitive: C4 – Case Studies
|
GNA11 Q209L
|
Uveal Melanoma
|
GNA11 Q209L
|
Uveal Melanoma
|
REC-4881 Sensitive: D – Preclinical
|
REC-4881 Sensitive: D – Preclinical
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
REC-4881 Sensitive: D – Preclinical
|
REC-4881 Sensitive: D – Preclinical
|
GNAQ Q209P
|
Uveal Melanoma
|
GNAQ Q209P
|
Uveal Melanoma
|
enzastaurin Sensitive: D – Preclinical
|
enzastaurin Sensitive: D – Preclinical
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
enzastaurin Sensitive: D – Preclinical
|
enzastaurin Sensitive: D – Preclinical
|
GNRH1 expression
|
Uveal Melanoma
|
GNRH1 expression
|
Uveal Melanoma
|
zoptarelin doxorubicin Sensitive: D – Preclinical
|
zoptarelin doxorubicin Sensitive: D – Preclinical
|
CDK9 overexpression
|
Uveal Melanoma
|
CDK9 overexpression
|
Uveal Melanoma
|
SNS-032 Sensitive: D – Preclinical
|
SNS-032 Sensitive: D – Preclinical
|
CDK7 overexpression
|
Uveal Melanoma
|
CDK7 overexpression
|
Uveal Melanoma
|
SNS-032 Sensitive: D – Preclinical
|
SNS-032 Sensitive: D – Preclinical
|
BAP1 mutation
|
Uveal Melanoma
|
BAP1 mutation
|
Uveal Melanoma
|
JNJ 26481585 Sensitive: D – Preclinical
|
JNJ 26481585 Sensitive: D – Preclinical
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
AEB071 Sensitive: D – Preclinical
|
AEB071 Sensitive: D – Preclinical
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
trametinib + GSK2126458 Sensitive: D – Preclinical
|
trametinib + GSK2126458 Sensitive: D – Preclinical
|
GNA11 Q209L
|
Uveal Melanoma
|
GNA11 Q209L
|
Uveal Melanoma
|
trametinib + GSK2126458 Sensitive: D – Preclinical
|
trametinib + GSK2126458 Sensitive: D – Preclinical
|
GNAQ Q209P
|
Uveal Melanoma
|
GNAQ Q209P
|
Uveal Melanoma
|
selumetinib + AZD8055 Sensitive: D – Preclinical
|
selumetinib + AZD8055 Sensitive: D – Preclinical
|
BRAF V600E
|
Uveal Melanoma
|
BRAF V600E
|
Uveal Melanoma
|
selumetinib + AZD8055 Sensitive: D – Preclinical
|
selumetinib + AZD8055 Sensitive: D – Preclinical
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
selumetinib + AZD8055 Sensitive: D – Preclinical
|
selumetinib + AZD8055 Sensitive: D – Preclinical
|
GNA11 mutation
|
Uveal Melanoma
|
GNA11 mutation
|
Uveal Melanoma
|
AEB071 + AHT956 Sensitive: D – Preclinical
|
AEB071 + AHT956 Sensitive: D – Preclinical
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
AEB071 + AHT956 Sensitive: D – Preclinical
|
AEB071 + AHT956 Sensitive: D – Preclinical
|
GNAQ Q209P
|
Uveal Melanoma
|
GNAQ Q209P
|
Uveal Melanoma
|
REC-4881 Sensitive: D – Preclinical
|
REC-4881 Sensitive: D – Preclinical
|
GNAQ Q209P
|
Uveal Melanoma
|
GNAQ Q209P
|
Uveal Melanoma
|
trametinib + GSK2126458 Sensitive: D – Preclinical
|
trametinib + GSK2126458 Sensitive: D – Preclinical
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
Tris DBA Sensitive: D – Preclinical
|
Tris DBA Sensitive: D – Preclinical
|
GNA11 mutation
|
Uveal Melanoma
|
GNA11 mutation
|
Uveal Melanoma
|
FR900359 Sensitive: D – Preclinical
|
FR900359 Sensitive: D – Preclinical
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
FR900359 Sensitive: D – Preclinical
|
FR900359 Sensitive: D – Preclinical
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
U0126 Sensitive: D – Preclinical
|
U0126 Sensitive: D – Preclinical
|
GNAQ Q209P
|
Uveal Melanoma
|
GNAQ Q209P
|
Uveal Melanoma
|
selumetinib Sensitive: D – Preclinical
|
selumetinib Sensitive: D – Preclinical
|
GNAQ Q209P
|
Uveal Melanoma
|
GNAQ Q209P
|
Uveal Melanoma
|
AEB071 Sensitive: D – Preclinical
|
AEB071 Sensitive: D – Preclinical
|
GNAQ Q209P
|
Uveal Melanoma
|
GNAQ Q209P
|
Uveal Melanoma
|
trametinib Sensitive: D – Preclinical
|
trametinib Sensitive: D – Preclinical
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
binimetinib + AEB071 Sensitive: D – Preclinical
|
binimetinib + AEB071 Sensitive: D – Preclinical
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
AEB071 + CGM097 Sensitive: D – Preclinical
|
AEB071 + CGM097 Sensitive: D – Preclinical
|
GNA11 mutation
|
Uveal Melanoma
|
GNA11 mutation
|
Uveal Melanoma
|
binimetinib + AEB071 Sensitive: D – Preclinical
|
binimetinib + AEB071 Sensitive: D – Preclinical
|
GNA11 mutation
|
Uveal Melanoma
|
GNA11 mutation
|
Uveal Melanoma
|
verteporfin Sensitive: D – Preclinical
|
verteporfin Sensitive: D – Preclinical
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
everolimus + AEB071 Sensitive: D – Preclinical
|
everolimus + AEB071 Sensitive: D – Preclinical
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
binimetinib + AEB071 Sensitive: D – Preclinical
|
binimetinib + AEB071 Sensitive: D – Preclinical
|
GNA11 mutation
|
Uveal Melanoma
|
GNA11 mutation
|
Uveal Melanoma
|
AEB071 + CGM097 Sensitive: D – Preclinical
|
AEB071 + CGM097 Sensitive: D – Preclinical
|
GNA11 mutation
|
Uveal Melanoma
|
GNA11 mutation
|
Uveal Melanoma
|
everolimus + AEB071 Sensitive: D – Preclinical
|
everolimus + AEB071 Sensitive: D – Preclinical
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
FR900359 Sensitive: D – Preclinical
|
FR900359 Sensitive: D – Preclinical
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
JQ-1 Sensitive: D – Preclinical
|
JQ-1 Sensitive: D – Preclinical
|
GNA11 mutation
|
Uveal Melanoma
|
GNA11 mutation
|
Uveal Melanoma
|
JQ-1 Sensitive: D – Preclinical
|
JQ-1 Sensitive: D – Preclinical
|
GNA11 mutation
|
Uveal Melanoma
|
GNA11 mutation
|
Uveal Melanoma
|
PD-0325901 + AEB071 Sensitive: D – Preclinical
|
PD-0325901 + AEB071 Sensitive: D – Preclinical
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
PD-0325901 + AEB071 Sensitive: D – Preclinical
|
PD-0325901 + AEB071 Sensitive: D – Preclinical
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
trametinib + hydroxychloroquine Sensitive: D – Preclinical
|
trametinib + hydroxychloroquine Sensitive: D – Preclinical
|
GNA11 Q209L
|
Uveal Melanoma
|
GNA11 Q209L
|
Uveal Melanoma
|
trametinib + hydroxychloroquine Sensitive: D – Preclinical
|
trametinib + hydroxychloroquine Sensitive: D – Preclinical
|
GNAQ Q209P
|
Uveal Melanoma
|
GNAQ Q209P
|
Uveal Melanoma
|
trametinib + hydroxychloroquine Sensitive: D – Preclinical
|
trametinib + hydroxychloroquine Sensitive: D – Preclinical
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
MEK inhibitor + YM-254890 Sensitive: D – Preclinical
|
MEK inhibitor + YM-254890 Sensitive: D – Preclinical
|
CYSLTR2 L129Q
|
Uveal Melanoma
|
CYSLTR2 L129Q
|
Uveal Melanoma
|
MEK inhibitor + YM-254890 Sensitive: D – Preclinical
|
MEK inhibitor + YM-254890 Sensitive: D – Preclinical
|
GNAQ R183Q
|
Uveal Melanoma
|
GNAQ R183Q
|
Uveal Melanoma
|
MEK inhibitor + YM-254890 Sensitive: D – Preclinical
|
MEK inhibitor + YM-254890 Sensitive: D – Preclinical
|
GNAQ G48V
|
Uveal Melanoma
|
GNAQ G48V
|
Uveal Melanoma
|
MEK inhibitor + YM-254890 Sensitive: D – Preclinical
|
MEK inhibitor + YM-254890 Sensitive: D – Preclinical
|